SynthesisAmerican journal of clinical dermatology2026
Is Acanthosis Nigricans a Marker for Metabolic Syndrome? A Systematic Review.
Synthesis in American journal of clinical dermatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
objectiveCertain skin conditions are proven indicators of underlying systemic disease. Specifically, acanthosis nigricans (AN) is commonly associated with type 2 diabetes and insulin resistance. However, AN may also be a marker of metabolic syndrome (MS). MS is linked to several health conditions leading to death. Therefore, early identification of MS is crucial in preventing disease progression. While AN may provide a visual cue for MS risk, its utility as a clinical screening tool remains underexplored. To address this, we conducted a systematic review to evaluate the association between AN and MS.
methodsWe systematically searched PubMed, Embase, and Cochrane Review using the term "acanthosis nigricans," identifying 656 articles, including 322 case reports, that reported AN in association with at least one MS criteria, as defined by the American Heart Association. Article quality was determined using the Strength of Recommendation Taxonomy (SORT) grading system.
resultsAcross the 656 included articles, the unweighted mean proportion of study participants with AN was 70.8% (standard deviation of 34.9%), reflecting that many studies evaluated broader patient populations in which AN was one of several conditions assessed. Of all MS criteria, insulin resistance showed the highest mean prevalence of AN at 72.6%. Within all articles, 65.9% met more than one MS criterion, with co-occurrence of insulin resistance and increased body mass being the most common combination (25.5%). In a subanalysis of non-case-report studies in which all participants had AN, 67.4% met the full criteria for MS, with increased body mass being the most frequently reported individual criterion (89.7% of cases).
conclusionsThis review provides a better estimate of AN observed in individuals with MS or in those at risk for MS. Integrating dermatologic examination for AN into primary care and preventive health may improve early detection of MS, reduce costs and unnecessary testing, and promote targeted interventions. Educational efforts are needed to increase clinician awareness of the association between AN and MS.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.